Pre-made Dusigitumab benchmark antibody ( Whole mAb, anti-IGF1;IGF2 therapeutic antibody, Anti-IGF/IGF-I/IGFI/MGF;C11orf43/GRDF/IGF-II/PP9974/SRS3 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-160

Pre-Made Dusigitumab biosimilar, Whole mAb, Anti-IGF1;IGF2 Antibody: Anti-IGF/IGF-I/IGFI/MGF;C11orf43/GRDF/IGF-II/PP9974/SRS3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGLF2.[1] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-160-1mg 1mg 3090 30% 2163

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Dusigitumab biosimilar, Whole mAb, Anti-IGF1;IGF2 Antibody: Anti-IGF/IGF-I/IGFI/MGF;C11orf43/GRDF/IGF-II/PP9974/SRS3 therapeutic antibody
INN Name Dusigitumab
TargetIGF1;IGF2
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesMedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer;Liver cancer;Solid tumours
Development Techna